42956-75-2

Basic information

• Product Name: N-HYDROXY-2,2-DIMETHYLPROPANIMIDAMIDE
• Synonyms: N-HYDROXY-2,2-DIMETHYLPROPANIMIDAMIDE;N'-Hydroxy-2,2-dimethylpropaneimideamide;N-Hydroxypivalimidamide
• CAS NO: 42956-75-2
• Molecular Formula: C₅H₁₂N₂O
• Molecular Weight: 116.16
• Product Categories: pharmacetical
• Mol File: 42956-75-2.mol
• Article Data: 25

Chemical Properties

• Melting Point: 113-115°
• Boiling Point: 214.3°Cat760mmHg
• Flash Point: 83.4°C
• Appearance: White to light brown/Powder
• Density: 1.01g/cm³
• CAS DataBase Reference: N-HYDROXY-2,2-DIMETHYLPROPANIMIDAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXY-2,2-DIMETHYLPROPANIMIDAMIDE(42956-75-2)
• EPA Substance Registry System: N-HYDROXY-2,2-DIMETHYLPROPANIMIDAMIDE(42956-75-2)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 42956-75-2(Hazardous Substances Data)

Usage

General Description

N-Hydroxy-2,2-dimethylpropanimidamide is a specialty chemical compound known for its unique and specific structural properties. It features a molecular formula of C5H12N2O which includes a combination of carbon, hydrogen, nitrogen, and oxygen atoms. This substance falls under the category of organic compounds which are rich in carbon content. As its name suggests, it has a hydroxy functional group combined with a 2,2-dimethylpropanimidamide group. Its properties and uses can greatly vary and could be applied to several industrial, chemical or pharmaceutical processes, depending primarily on the nature of its combination or reaction with other substances. Specific degradation rates, toxicity levels, or safety measures can also be established once its interaction with environmental elements is determined.

Upstream product

• 630-18-2 tert-butyl isocyanide 
• 630-19-3 pivalaldehyde 
• 637-91-2 2,2-dimethylpropionaldehyde oxime 

Downstream Products

• 906540-97-4 N'-[[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]carbonyl]oxy]-2,2-dimethylpropanimidamide 
• 1030019-58-9 C₂₀H₁₇ClF₂N₆O₂ 
• 1046271-00-4 1-[5-(3-cyclohexyl-[1,2,4]oxadiazol-5-yl)-2-methyl-benzenesulfonyl]-piperidine 
• 1146089-74-8 5-{4-[1-(3-tert-butyl-[1,2,4]oxadiazol-5-ylmethyl)azetidin-3-yloxy]phenyl}-2-methanesulfonylpyridine 
• 1196103-39-5 3-tert-butyl-5-[1-methyl-1-(4-trifluoromethyl-benzenesulfonyl)-ethyl]-[1,2,4]oxadiazole 
• 844875-60-1 C₂₉H₃₅N₅O₄ 
• 1327278-69-2 3-tert-butyl-5-(4-vinylphenyl)-1,2,4-oxadiazole 
• 1327278-72-7 3-tert-butyl-5-(4-ethylphenyl)-1,2,4-oxadiazole 
• 1327278-70-5 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole 
• 1327278-71-6 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzaldehyde 
• 1415140-62-3 3-(tert-butyl)-5-(4-((3-fluorophenyl)ethynyl)phenyl)-1,2,4-oxadiazole 
• 1502807-46-6 methyl 4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4-oxobutanoate 
• 1502807-45-5 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)pyrrolidine-2,5-dione 
• 1502807-47-7 (Z)-4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4-oxobut-2-enoic acid 

Relevant articles and documents

Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses

This article describes the synthesis and antiviral activity evaluation of new substituted 1,2,4-oxadiazoles containing a bicyclic substituent at position 5 of the heterocycle and O-acylated amidoximes as precursors for their synthesis. New compounds were

SSAO INHIBITOR

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.